• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA staff raises concerns on Geron's blood disorder drug

cafead

Administrator
Staff member
  • cafead   Mar 12, 2024 at 11:22: AM
via The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's (GERN.O) blood disorder drug provided a clear benefit to patients in a late-stage trial and raised multiple safety concerns with the treatment.

article source